The primary endpoint, a composite of coronary, cerebrovascular and peripheral macrovascular events, showed a trend towards benefit from pioglitazone.
← all excerpts
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.
1
—
—